And for its part, Insilico could benefit from greater visibility and access to more resources. The collaboration with Pfizer follows a busy two years for Insilico — during which the company secured deals with Elevian, TARA Biosystems, and WuXi AppTec, and raised $37 million in financing, hauling its total funding to date past $51 million, Crunchbase.
We think this tie-up could signal a huge opportunity for startups working in AI-powered drug discovery — and with the Pfizer name attached, there's an added air of legitimacy. The impact of the deal between Insilico and Pfizer could lead other AI biotech startups to throw their hats in the ring and more aggressively pursue tie-ups with major pharma players.
Additionally, the fact that a big-name pharma firm is sinking cash into the startup adds an increased sense of legitimacy to AI startups operating in the drug discovery realm — and we wouldn't be surprised to see However, we think it's possible we could see pharma companies pursue a strategy of scooping up these startups to move AI capabilities in-house, as we know that pharma companies aren't strangers when it comes to mergers and acquisition activity: Pharma and biotech firms...
We don't need pfizer
But will they? If they do, will other's follow..?
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »